Methylophiopogonanone A Protects against Cerebral Ischemia/Reperfusion Injury and Attenuates Blood-Brain Barrier Disruption In Vitro

PLoS One. 2015 Apr 21;10(4):e0124558. doi: 10.1371/journal.pone.0124558. eCollection 2015.

Abstract

Methylophiopogonanone A (MO-A), an active homoisoflavonoid of the Chinese herb Ophiopogon japonicus which has been shown to have protective effects on cerebral ischemia/reperfusion (I/R) injury, has been demonstrated to have anti-inflammatory and anti-oxidative properties. However, little is known about its role in cerebral I/R injury. Therefore, in this study, by using a middle cerebral artery occlusion (MCAO) and reperfusion rat model, the effect of MO-A on cerebral I/R injury was examined. The results showed that MO-A treatment reduced infarct volume and brain edema, improved neurological deficit scores, reversed animal body weight decreases, and increased animal survival time in the stroke groups. Western blotting showed that MO-A suppressed MMP-9, but restored the expression of claudin-3 and claudin-5. Furthermore, transmission electron microscopy were monitored to determine the blood-brain barrier (BBB) alterations in vitro. The results showed that MO-A markedly attenuated BBB damage in vitro. Additionally, MO-A inhibited ROS production in ECs and MMP-9 release in differentiated THP-1 cells in vitro, and suppressed ICAM-1 and VCAM-1 expression in ECs and leukocyte/EC adhesion. In conclusion, our data indicate that MO-A has therapeutic potential against cerebral I/R injury through its ability to attenuate BBB disruption by regulating the expression of MMP-9 and tight junction proteins.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Benzodioxoles / pharmacology*
  • Benzodioxoles / therapeutic use
  • Blood-Brain Barrier / drug effects*
  • Blood-Brain Barrier / metabolism
  • Cell Adhesion
  • Cell Line
  • Drug Evaluation, Preclinical
  • Endothelium, Vascular / pathology
  • Humans
  • Infarction, Middle Cerebral Artery / complications
  • Infarction, Middle Cerebral Artery / drug therapy*
  • Isoflavones / pharmacology*
  • Isoflavones / therapeutic use
  • Leukocytes / physiology
  • Male
  • Mice
  • Neuroprotective Agents / pharmacology*
  • Neuroprotective Agents / therapeutic use
  • Rats, Sprague-Dawley
  • Reactive Oxygen Species / metabolism
  • Reperfusion Injury / etiology
  • Reperfusion Injury / prevention & control*

Substances

  • Benzodioxoles
  • Isoflavones
  • Neuroprotective Agents
  • Reactive Oxygen Species
  • methylophiopogonanone A

Grants and funding

The current study was supported by research grants from the National Twelfth-Five Year Research Program of China (2012ZX09301002001002), the National Natural Science Foundation of China (Grant No. 81473398) and the scientific research foundation of Beijing Friendship Hospital (Z20140512030022). The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.